Serum vitamin d and risk of prostate cancer in a case-control analysis nested within the european prospective investigation into cancer and nutrition (EPIC)

American Journal of Epidemiology

Volumn 169, Issue 10, 2009, Pages 1223-1232

  Travis, Ruth C ^b   Crowe, Francesca L ^a   Allen, Naomi E ^b   Appleby, Paul N ^b   Roddam, Andrew W ^b   Tjønneland, Anne ^b   Olsen, Anja ^b   Linseisen, Jakob ^b   Kaaks, Rudolf ^b   Boeing, Heiner ^b   Kröger, Janine ^b   Trichopoulou, Antonia ^b   Dilis, Vardis ^b   Trichopoulos, Dimitrios ^b   Vineis, Paolo ^b   Palli, Domenico ^b   Tumino, Rosario ^b   Sieri, Sabina ^b   Bueno De Mesquita, H Bas ^b   Van Duijnhoven, Fränzel J B ^b   Chirlaque, María Dolores ^b   Barricarte, Aurelio ^b   Larrañaga, Nerea ^b   González, Carlos A ^b   Argüelles, Marcial V ^b   Sánchez, Maria José ^b   Stattin, Pär ^b   Hallmans, Göran ^b   Khaw, Kay Tee ^b   Bingham, Sheila ^b   Rinaldi, Sabina ^b   Slimani, Nadia ^b   Jenab, Mazda ^b   Riboli, Elio ^b   Key, Timothy J ^b   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE

Author keywords

25 hydroxyvitamin D 2; Prostatic neoplasms; Serum; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D;

BLOOD; CANCER; CONCENTRATION (COMPOSITION); DISEASE CONTROL; HEALTH RISK; NUTRITION; SERUM; VITAMIN;

ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; EUROPE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL ASSESSMENT; PROSTATE CANCER; VITAMIN BLOOD LEVEL;

AGED; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; EUROPE; GREAT BRITAIN; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NUTRITIONAL STATUS; ODDS RATIO; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SEASONS; VITAMIN D;

EID: 65949109925     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp022     Document Type: Article

References (32)

1. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990; 10(5A):1307-1311.
2. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. J Bone Miner Res. 1998;13(3):325-349.
3. 2 in the treatment of advanced androgenindependent prostate cancer. Clin Cancer Res. 2003;9(11): 4077-4083.
4. 3 on primary cultures of human prostatic cells. Cancer Res. 1994;54(3):805-810.
5. Ahn J, Peters U, Albanes D, et al. Serum vitamin D concentration and prostate cancer risk: A nested case-control study. J Natl Cancer Inst. 2008;100(11):796-804.
6. Ahonen MH, Tenkanen L, Teppo L, et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitaminDlevels (Finland). Cancer Causes Control. 2000;11(9):847-852.
7. Braun MM, Helzlsouer KJ, Hollis BW, et al. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control. 1995;6(3): 235-239.
8. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993;2(5):467-472.
9. Faupel-Badger JM, Diaw L, Albanes D, et al. Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2784-2786.
10. Gann PH, Ma J, Hennekens CH, et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996;5(2): 121-126.
11. Jacobs ET, Giuliano AR, Martínez ME, et al. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol. 2004; 89-90(1-5):533-537.
12. Li H, Stampfer MJ, Hollis JB, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007;4(3):562-571.
13. Nomura AM, Stemmermann GN, Lee J, et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control. 1998;9(4):425-432.
14. Platz EA, Leitzmann MF, Hollis BW, et al. Plasma 1,25-dihydroxy-and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control. 2004;15(3): 255-265.
15. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries. Int J Cancer. 2004;108(1):104-108.
16. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research; 2007.
17. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684-700.
18. Holick MF. Medical progress: Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.
19. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): Study populations and data collection. Public Health Nutr. 2002;5(6B): 1113-1124.
20. Key TJ, Appleby PN, Allen NE, et al. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007;86(3):672-681.
21. Margetts BM, Pietinen P. European Prospective Investigation into Cancer and Nutrition: Validity studies on dietary assessment methods. Int J Epidemiol. 1997;26(suppl 1):S1-S5.
22. Rosner B. A generalization of the paired t-test. Appl Stat. 1982;31(1):9-13.
23. 3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993; 132(5):1952-1960.
24. Schwartz GG, Wang MH, Zhang M, et al. 1 alpha,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 1997;6(9):727-732.
25. Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest. 2005;35(5):290-304.
26. 3. Cancer Epidemiol Biomarkers Prev. 1998;7(5): 391-395.
27. Chan JM, Giovannucci EL. Dairy products, calcium, and vitamin D and risk of prostate cancer. Epidemiol Rev. 2001; 23(1):87-92.
28. Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006; 92(1):4-8.
29. Corder EH, Friedman GD, Vogelman JH, et al. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: Risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev. 1995;4(6):655-659.
30. Mikhak B, Hunter DJ, Spiegelman D, et al. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate. 2007;67(9):911-923.
31. Lauridsen AL, Vestergaard P, Hermann AP, et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D are related to the phenotype of Gc (vitamin D- binding protein): A cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int. 2005;77(1):15-22.
32. Etzioni R, Cha R, Feuer EJ, et al. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol. 1998;148(8): 775-785.